Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
about
Discovery, Synthesis, and Structure–Activity Relationship of a Series of N -Aryl-bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel OpenerElectrogenic tuning of the axon initial segmentNeural KCNQ (Kv7) channelsNew molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channelsRetigabine: has the orphan found a home?Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based ReviewAntiepileptic Drug Treatment in Children with EpilepsyRecent treatment advances and novel therapeutic approaches in epilepsyACS chemical neuroscience molecule spotlight on Potiga (Ezogabine)New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapySafety and tolerability of perampanel: a review of clinical trial data.Ezogabine skin discoloration is reversible after discontinuationRetigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug-drug interaction study.Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration.Expression and function of the K+ channel KCNQ genes in human arteries.Emerging drugs for epilepsy.New antiepileptic medication linked to blue discoloration of the skin and eyesEzogabine: a new angle on potassium gates.Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizuresTime to prerandomization monthly seizure count in perampanel trials: A novel epilepsy endpointNeuronal potassium channel openers in the management of epilepsy: role and potential of retigabine.Clinical utility of adjunctive retigabine in partial onset seizures in adults.Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy.Evaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis.New developments in the treatment of partial-onset epilepsy.Antiepileptic drugs 2012: recent advances and trends.Recent new drug approvals, part 2: drugs undergoing active clinical studies in childrenAntiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study.Ezogabine (KCNQ2/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression.Somatostatin: an endogenous antiepilepticA KCNQ channel opener for experimental neonatal seizures and status epilepticusAction potential initiation and propagation: upstream influences on neurotransmissionK+ channel modulators for the treatment of neurological disorders and autoimmune diseasesEfficacy of retigabine in adjunctive treatment of partial onset seizures in adults.Pharmacokinetic and pharmacodynamic properties of the new AEDs: A review articleAdolescent Clinical Development of Ezogabine/Retigabine as Adjunctive Therapy for Partial-Onset Seizures: Pharmacokinetics and Tolerability.The contribution of Kv7 channels to pregnant mouse and human myometrial contractility.Pharmacotherapy of epilepsy: newly approved and developmental agents.Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis.
P2860
Q24634116-F0A7A217-A0E8-4890-A8FD-9A5F81853A76Q24634301-DECBDE3D-6550-466A-9324-93A623CF7E37Q24644947-A54E17CE-F8AF-4F9E-93C6-900D61FD965BQ24654230-C7F6D3E1-DC15-419E-A0DD-AE8C746C65ADQ24685444-75211EE4-AC90-428A-AE8A-FCA0A5596150Q26743786-8BEA22E2-C049-4DFC-B452-DFB96106A2F1Q26781771-C354CDFD-23A0-4769-B1A3-42673D9E7E5FQ26824512-A809BBAF-2F6D-452A-A606-368FBBCE2E8AQ26851224-E20BA47A-690A-455E-BC73-4FA9D2567058Q27007942-5C47B148-3BE1-4386-A26D-1D073CA181A8Q30597533-A010F512-A655-49CA-B7AE-A19256EF1386Q33555698-0EE5A072-1DD5-4D69-8E24-AD8E552E3CB7Q34333196-7D2EB335-CFBF-454D-8C33-B9BE71A43426Q34386899-523FED03-9138-41C5-A1E3-219E4D21AE67Q34390785-3359FFD1-42B8-446F-B361-2E6DDAD82C2DQ34449702-725821CC-EA5F-41EE-B4AE-BCF466BB5C9EQ34688725-0CBDD249-8C15-4074-9D12-5F620403B951Q35019465-68897D6E-A5EF-4F23-A10E-E92C747B60D3Q35052160-E26656DF-1100-4D1E-84BA-9431A241FA2AQ35117817-837B3542-16EE-4C09-9B3C-F2A52F164C95Q35639962-AB56F3C1-0243-411B-9135-BDA28DE3D59DQ35683922-0996748F-5BDB-48B6-B2C8-AAF76E3E4F1FQ35717049-7923F956-E17D-46F6-A23E-8E1A8F7BD56EQ36144410-31F1FAD5-C948-473D-843E-9F380C5DE828Q36284727-BEF1881B-423E-4E76-BE7F-8669AECA48FDQ36337897-6BF148E9-5A34-4BFA-A4EC-EEB4EEDF3993Q36513108-DC356084-8398-4B27-B3FD-C06465DBA876Q36764984-D827DDC8-6554-449D-A91C-FB08FE367C99Q36958975-FAE610CC-544B-4B53-9A23-60822457B407Q36980156-D8D164F4-663F-44E5-9DD7-FF18E0A12647Q37067748-E2911B13-2540-46F0-A8CF-6218FF1E304CQ37151699-EDFFE371-A503-4D41-B9F4-56E41EA4D959Q37160148-68E3718E-0BCB-452D-9137-04DE7FC7B288Q37162392-09792D4A-40C3-4814-96FA-FFF903A79127Q37302567-E4A225BE-71C7-4F12-A973-A4AA41918498Q37311819-6CC1AFC5-000B-49DD-B872-0C7519C0FA0DQ37406223-F2D8484F-245B-42E2-A3AA-0596C79DBB9FQ37580235-29CFBED8-78A6-4B97-BF24-9D5652648055Q37831297-73A97CE6-AB44-4C6D-AD92-A2B3D10AAC34Q37832531-6DEAD0BF-A116-4CB2-B2D3-A4AC04CE3D8F
P2860
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
@ast
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
@en
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
@nl
type
label
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
@ast
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
@en
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
@nl
prefLabel
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
@ast
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
@en
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
@nl
P2093
P1433
P1476
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
@en
P2093
205 Study Group
R J Porter
P304
P356
10.1212/01.WNL.0000259034.45049.00
P407
P577
2007-04-01T00:00:00Z